Release issued 4th August 2008

BioAlliance Pharma SA complements its portfolio with a European license for ondansetron RapidFilm(TM)

Paris, 4 August, 2008 - BioAlliance Pharma SA. (Euronext Paris ISIN code: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, and APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, today announced that they have entered into an exclusive licensing agreement under which BioAlliance has acquired the commercialization rights in Europe to the thin film formulation of ondansetron from APR/Labtec, leader in oral thin film technology named RapidFilmTM. Ondansetron thin film formulation is a new oral formulation for the prevention of chemotherapy-induced nausea and vomiting, prevention of nausea and vomiting associated with radiotherapy, and post-operative nausea and vomiting.

Based on the results of a recently completed bio-equivalency study, BioAlliance will be preparing registration in Europe. The exclusive license to BioAlliance may total up to EUR 6.0 million with EUR 1 million at signature and EUR 1,25 million at approval and sales milestones up to EUR 3,75 million; in addition royalties on net sales of the product will also be paid.

Anti-emetic therapies constitute one of the largest segments of the supportive care market in Europe, with annual sales of over EUR 400 million in 2007 in the 5 major EU markets (IMS Midas 2007). Ondansetron was the prescription leader in the category in 2007, with about 800 000 prescriptions (as extrapolated from IMS Midas Medical Data 2007).

APR/Labtec's proprietary RapidFilmTM technology is a novel, non- mucoadhesive, fast dissolving oral dosage form. It features a thin film based on a water-soluble polymer. The film disintegrates rapidly within seconds in contact with water or saliva, releases the drug in the mouth and promotes gastrointestinal absorption. The RapidFilmTM dosage form was especially designed for high patient compliance. The application is easy. The patient does not have any swallowing difficulty. The fact that no water intake after administration is needed is very well accepted by patients with nausea.

Dominique Costantini, CEO of BioAlliance said, "We are delighted to collaborate with APR/Labtec and expand our pipeline of supportive care products. With two unique, yet complementary delivery systems of ondansetron in our portfolio, ondansetron oral spray from NovaDel and the oral thin film, we are able to offer patients a better opportunity to find a product that meets their individual needs.

Paolo Galfetti, CEO of APR, stated, "BioAlliance is uniquely positioned to market and sell our ondansetron thin film product and we are very excited about the collaboration. Following approval, ondansetron is expected to be the first prescription drugs to come to market utilizing thin film drug delivery technology".

(26th November 2008) tesa AG Acquires Labtec GmbH

(29th January 2008) APR Applied Pharma Research s.a. ("APR") and Labtec GmbH ("Labtec") Announce the Successful Completion of the Pilot Bioequivalence Study of Their Donepezil RapidFilm

(15th January 2008) Successful completion of Pivotal Bioequivalence study for Ondansetron RapidFilm

(25th April 2007) Labtec's next generation pain patch successful in clinical studies

(5th January 2007) First continuous combined hormone replacement patch approved for marketing in Europe